ONCOVIRX.COM
Home -OncoViRxOncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program.
http://www.oncovirx.com/
OncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program.
http://www.oncovirx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
10.4 seconds
16x16
PAGES IN
THIS WEBSITE
7
SSL
EXTERNAL LINKS
1
SITE IP
107.180.50.244
LOAD TIME
10.437 sec
SCORE
6.2
Home -OncoViRx | oncovirx.com Reviews
https://oncovirx.com
OncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program.
oncovirx.com
Publications -OncoViRx
http://oncovirx.com/publications
Research & Development. Our Pipeline – Small Molecule Inhibitors. Banerjee, S., Lu, J., Cai, Q., Sun, Z., Jha, H., and Robertson, E. (2014). EBNA3C Augments Pim-1 Mediated Phosphorylation and Degradation of p21 to Promote B-Cell Proliferation. Dzeng, R., Jha, H., Lu, J., Saha, A., Banerjee, S., and Robertson, E. (n.d.). Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cells. Journal of Virology,. Proceedings of the National Academy of Sciences,. Cancer Biology and Therapy,.
Sitemap -OncoViRx
http://oncovirx.com/sitemap
Research & Development. Our Pipeline – Small Molecule Inhibitors. Our Pipeline – Small Molecule Inhibitors. 3401 Grays Ferry Ave. Bldg 212, Suite 136. Philadelphia, PA 19146. Website was created by Advantadna.com.
News -OncoViRx
http://oncovirx.com/news
Research & Development. Our Pipeline – Small Molecule Inhibitors. January 24, 2017. Money Matters TV 16-46 with Francis Humann. NEWS Money Matters TV 16-46 with Francis Humann. Do you like it? February 24, 2016. Francis Humann Joins OncoViRx As CEO and President. NEWS Francis Humann Joins OncoViRx As CEO and President Francis brings over 17 years of pharmaceutical industry experience at Pfizer, Wyeth, and Abbott in product launch […]. Do you like it? 3401 Grays Ferry Ave. Bldg 212, Suite 136.
Company Overview -OncoViRx
http://oncovirx.com/overview
Research & Development. Our Pipeline – Small Molecule Inhibitors. B, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia. Two of these compounds, which are in the same class, have been selected for further development, and the Winkler Laboratory is now developing analogs of these compounds. Our goal is to develop novel treatments that are efficacious, have reduced short and long term ...
Our Pipeline - Small Molecule InhibitorsOncoViRx
http://oncovirx.com/small-molecule-inhibitors
Research & Development. Our Pipeline – Small Molecule Inhibitors. OUR PIPELINE - SMALL MOLECULE INHIBITORS. OncoViRx is developing therapeutics to target specific mechanisms of oncogenesis. Specifically, the company is primarily focusing on compounds for inhibition of c-MYC, and NF- K. B, and secondarily Notch1. Within the next 12 months, our plan is to develop a number of additional analogs, complete. Screening, and then advance the most promising candidates into a pilot. Study We anticipate initial cli...
TOTAL PAGES IN THIS WEBSITE
7
Therapeutics Archives - Penn Center for Innovation
http://www.pci.upenn.edu/portfolio/therapeutics
Penn Center for Innovation. Penn-owned tech available for licensing. Leading Innovation at Penn. Partners & Friends. Entrepreneurial Resources (PCI Ventures). Innovation & Entrepreneurship Resources at Penn. Penn-owned tech available for licensing. Leading Innovation at Penn. Partners & Friends. Entrepreneurial Resources (PCI Ventures). Innovation & Entrepreneurship Resources at Penn. Cellular immunotherapy for solid tumors. ( Saar Gill. Novel therapeutics to modulate skin pigmentation. ( Todd Ridky.
TOTAL LINKS TO THIS WEBSITE
1
Oncovip Medicina Preventiva / Home
Central (511)224-2704 (511)224-6638 ( San Borja. 511)535-4029 ( Los Olivos. Somos un Centro de Medicina Preventiva, representantes en el Perú de Pathway Genomics, especializado en la investigación seria, exhaustiva y minuciosa de la patología humana, que pone a su disposición una variedad de servicios exclusivos, para un diagnóstico preciso con equipos de última generación, incluyendo la detección genética de diversos tipos de cáncer y enfermedades crónicas. Dr Juan C. Delgado. Dr Julio Rios Urrutia.
OncoVIP.it
Egrave; possibile accedere con le proprie credenziali di MSD Salute:. Se non sei iscritto registrati gratuitamente. Online su MSD Salute o telefona al Numero Verde 800 239989. Le ultime novità dalla voce dei nostri esperti. Le ultime novità dalla voce dei nostri esperti. Carcinoma polmonare NSCLC, pembrolizumab vincente anche in termini di qualità di vita. Metastasi cerebrali da melanoma. Melanoma avanzato, strategie terapeutiche sempre più articolate.
Oncovir, Inc.
Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Oncovir promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. Get in touch with us at:.
oncovirus.com
Home - OncoViRxOncoViRx
Research & Development. Our Pipeline – Small Molecule Inhibitors. Targeted small molecule therapy for difficult-to-treat hematologic malignancies. B, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia. Approximately every 3 minutes one person in the United States is diagnosed with a blood cancer. Approximately every 10 minutes one person in the United States dies from a blood cancer.
Home -OncoViRx
Research & Development. Our Pipeline – Small Molecule Inhibitors. Targeted small molecule therapy for difficult-to-treat hematologic malignancies. B, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia. Approximately every 3 minutes one person in the United States is diagnosed with a blood cancer. Approximately every 10 minutes one person in the United States dies from a blood cancer.
Oncovision
Wednesday, November 11, 2009. Advertisement for the Valor Enric. TREASURE HUNT FOR STUDENTS. This is a call to Enric Valor Students. THE FOURTEENTH word is TRINQUET. The following THING TO DO IS TO COMPOSE THE SENTENCE AND ACT ACCORDING TO IT. THE TREASURE IS WAITING FOR THE FIRST ONE! Wednesday, July 16, 2008. Oncovision developing the BRAIN-PET. Spanish scientists develop a tomographic camera that will allow to anticipate five years Alzheimer diagnose. Mon, 11/02/2008 - 10:27 —. Benlloch has pointed th...
Domain Default page
If you are seeing this message, the website for is not available at this time. If you are the owner of this website, one of the following things may be occurring:. You have not put any content on your website. Your provider has suspended this page. Please login to to receive instructions on setting up your website. This website was created using our Parallels Panel product. We offer a full line of Billing, Sitebuilder and cloud computing tools. Please visit www.parallels.com. To find out more information.
Domain suspended
Contact your internet service provider. Internet Corporation for Assigned Names and Numbers - has introduced the Expired Registration Recovery Policy (ERRP). Are you the domain owner? Your internet service provider to renew the domain. In order to avoid cancellation and to bring back immediately online your website.
06644com开奖号码,香港金光佛888840,cmm|奇人论坛833658开奖结果香港马
Profile & Milestones. In providing innovative, safe and efficacious treatments for cancer. OncoVista Innovative Therapies, Inc. OTCBB: OVIT) is a drug development company engaged in the development and commercialization of targeted cancer therapies. OncoVista produces innovative drug discovery, registration strategies and emerging technologies, allowing the company to bring to market less toxic and highly effective anti-cancer drugs. The company engages in the development and commercialization of...OncoV...
